Motley Fool
Is 23andMe a Buy at $11?
Freshly listed on the NASDAQ following a business combination with VG Acquisition Corp, a special purpose acquisition company (SPAC), the consumer genetic-testing maven 23andMe (NASDAQ: ME) is at the very start of its growth story. In my view, this stock’s growth story justifies its current price, but you’ll need to hold onto it for a few years before seeing returns skyrocket. 23andMe’s direct-to-consumer health service is the company’s staple offering; it provides information on genetic risk factors for a handful of different diseases.
